Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Invest. clín ; 33(2): 61-7, 1992. tab
Article Dans Espagnol | LILACS | ID: lil-121956

Résumé

Nitrendipine (NIT), a new potent calcium channel blockingagent, was administered to a patient with essential severe (191/119 mm Hg), refractory, and resistant hypertension (HT) to conventional triple drug regime. Three previous pregnancies had been insuccessful in the past 4 years because of uncontrollable HT and repeated hypertensive crisisses. NIT (20 mg tablets) was given PO as a single morning dose and 15 months after BP control, she became pregnant again. With a 20 mg/day dose of NIT throughout pregnancy, a healthy 2400 g. 47 cm male boy was delivered by a non-emergency cesarean section at 37 weeks pregnancy. Both mother and con remain normal months after birth. The results suggest NIT may be considered as an alternative for this type of patients and should be studied in clinical trials


Sujets)
Adulte , Humains , Femelle , Hypertension artérielle/thérapie , Hypertension artérielle , Nitrendipine/usage thérapeutique , Grossesse/complications
SÉLECTION CITATIONS
Détails de la recherche